肝硬化慢乙肝完全病毒抑制后HBsAg清除进一步降低肝癌风险但不减少肝功能失代偿
本研究基于2005至2020年接受恩替卡韦/替诺福韦治疗的成人慢乙肝肝硬化患者队列,1年landmark分析纳入5149例。中位随访4.1年,HBsAg清除者肝细胞癌风险显著低于单纯完全病毒抑制者(校正亚分布HR 0.37,95%CI 0.15-0.91,P=0.030),但肝脏事件风险无差异(校正亚分布HR 1.01,95%CI 0.52-1.95)。
要点
- 肝硬化慢乙肝完全病毒抑制者中,HBsAg清除与肝癌风险降低相关(校正亚分布HR 0.37)。
- HBsAg清除未显著降低肝脏失代偿事件风险(校正亚分布HR 1.01)。
- 2年landmark分析中HBsAg清除对肝癌的关联方向一致(校正亚分布HR 0.37)。
核心结论
- 在核苷(酸)类似物治疗且完全病毒抑制的慢乙肝肝硬化患者中,HBsAg清除与肝细胞癌风险降低相关,但与首次或进一步肝功能失代偿无关。
研究设计与样本
- 研究纳入2005年1月至2020年9月接受恩替卡韦/替诺福韦治疗的成人慢乙肝肝硬化患者,排除基线时或基线后6个月内发生肝癌、基线前其他癌症或肝移植、HBsAg清除前肝移植及未达完全病毒抑制者。
- 采用1年landmark分析,排除1年内出现临床结局或随访不足1年者,最终5149例纳入分析(平均年龄60.1±12.6岁,男性66.3%)。
主要发现
- 中位随访4.1(25th-75th百分位2.5-5.0)年,单纯完全病毒抑制组4988例中456例(9.1%)发生肝癌,HBsAg清除组161例中5例(3.1%)发生肝癌。
- 单纯完全病毒抑制组4777例中334例(7.0%)发生肝脏事件,HBsAg清除组153例中10例(6.5%)发生肝脏事件。
- HBsAg清除与肝癌风险降低相关(校正亚分布HR 0.37,95%CI 0.15-0.91,P=0.030),与肝脏事件风险无关(校正亚分布HR 1.01,95%CI 0.52-1.95)。
- 2年landmark分析中HBsAg清除对肝癌的关联相似(校正亚分布HR 0.37,95%CI 0.14-1.04)。
临床怎么用
- 对于已实现完全病毒抑制的慢乙肝肝硬化患者,HBsAg清除可作为进一步降低肝癌风险的获益指标,但仍需关注肝功能失代偿风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Whether HBsAg seroclearance provides further clinical benefit over complete viral suppression in nucleos(t)ide analogue (NA)-treated patients with chronic hepatitis B with cirrhosis remained unclear. We aimed to compare the risk of HCC and hepatic decompensation in treated patients with cirrhosis with complete viral suppression versus HBsAg seroclearance. APPROACH AND RESULTS: All adult patients with chronic hepatitis B and cirrhosis receiving entecavir/tenofovir between January 2005 and September 2020 were identified. Patients with HCC before or within the first 6 months of baseline, other cancers or liver transplantation before baseline, liver transplantation before HBsAg loss, and without complete viral suppression were excluded. One-year landmark analyses were performed; patients with clinical outcomes or follow-up <1 year were excluded. Of 5149 patients (mean age 60.1±12.6 y, 66.3% male) included in the 1-year landmark analysis, 456/4988 (9.1%) and 5/161 (3.1%) of patients with complete viral suppression alone and HBsAg seroclearance developed HCC, respectively, at a median (25th-75th percentile) follow-up of 4.1 (2.5-5.0) years; 334/4777 (7.0%) and 10/153 (6.5%) patients with complete viral suppression and HBsAg loss developed hepatic events. HBsAg seroclearance was associated with a lower risk of HCC (adjusted subdistribution HR: 0.37, 95% CI 0.15-0.91, p =0.030) but not hepatic events (adjusted subdistribution HR: 1.01, 95% CI: 0.52-1.95) than complete viral suppression. Similar results on HCC were observed in a 2-year landmark analysis (adjusted subdistribution HR: 0.37 [0.14-1.04]). CONCLUSIONS: HBsAg seroclearance is associated with a lower risk of HCC but not first/further hepatic decompensation in NA-treated patients with chronic hepatitis B and cirrhosis with complete viral suppression.
引用
- Hui VW, Tang JC, Wong VW, et al. HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppression. Hepatology. 2026. PMID: 42263224. doi:10.1097/HEP.0000000000001804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。